Compare SCVL & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCVL | ZURA |
|---|---|---|
| Founded | 1978 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 491.1M | 521.8M |
| IPO Year | 1994 | N/A |
| Metric | SCVL | ZURA |
|---|---|---|
| Price | $17.20 | $5.34 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 418.7K | ★ 603.2K |
| Earning Date | 05-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $1,135,324,000.00 | N/A |
| Revenue This Year | $1.64 | N/A |
| Revenue Next Year | $2.51 | N/A |
| P/E Ratio | $9.68 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.04 | $0.99 |
| 52 Week High | $26.54 | $7.25 |
| Indicator | SCVL | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 41.99 | 44.95 |
| Support Level | $16.80 | $5.28 |
| Resistance Level | $18.37 | $5.82 |
| Average True Range (ATR) | 0.72 | 0.35 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 12.14 | 46.97 |
Shoe Carnival Inc is a family footwear retailer that offers a broad assortment of dress, casual, and athletic footwear for men, women, and children with an emphasis on national name brands such as Nike, Skechers, Adidas, Puma, HEYDUDE, Converse, Vans, and Crocs. The company operates its business as one reportable segment based on the similar nature of products sold; merchandising, distribution, and marketing processes involved; target customers; and economic characteristics of stores and e-commerce platforms. Its bricks-first, omnichannel approach provides customers easy access to a wide assortment of branded footwear for work, athletics, daily activities, and special events via a choice of delivery channels.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.